Cardlytics (CDLX) Tops Q2 EPS by 26c, provides guidance

Cardlytics (NASDAQ: CDLX) reported Q2 EPS of ($0.13), $0.26 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $63.2 million versus the consensus estimate of $64.06 million.

GUIDANCE:

Cardlytics sees Q3 2025 revenue of $52.2-58.2 million, versus the consensus of $67.326 million.

For earnings history and earnings-related data on Cardlytics (CDLX) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Tops Q2 EPS by $6.60, Beats on Revenue
• Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure
• TD Cowen Upgrades Newmont Mining Corp. (NEM) to Buy